Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics
Fluorescence imaging in the second near-infrared window (NIR-II) has become a prevalent
choice owing to its appealing advantages like deep penetration depth, low …
choice owing to its appealing advantages like deep penetration depth, low …
Potential of copper and copper compounds for anticancer applications
P Ji, P Wang, H Chen, Y Xu, J Ge, Z Tian, Z Yan - Pharmaceuticals, 2023 - mdpi.com
Inducing cancer cell death has always been a research hotspot in life sciences. With the
continuous deepening and diversification of related research, the potential value of metal …
continuous deepening and diversification of related research, the potential value of metal …
An AND Logic Gate for Magnetic‐Resonance‐Imaging‐Guided Ferroptosis Therapy of Tumors
To improve the magnetic resonance imaging (MRI) efficiency and ferroptosis therapy
efficacy of exceedingly small magnetic iron oxide nanoparticles (IO,< 5 nm) for tumors via …
efficacy of exceedingly small magnetic iron oxide nanoparticles (IO,< 5 nm) for tumors via …
Biocatalytic cascade in tumor microenvironment with a Fe2O3/Au hybrid nanozyme for synergistic treatment of triple negative breast cancer
Designing nanozyme hybrids with cascade catalytic activities and coupling effects has
significant promises in tumor therapy through concerted effects. In this work, a goethite …
significant promises in tumor therapy through concerted effects. In this work, a goethite …
Reticular Chemistry‐Enabled Sonodynamic Activity of Covalent Organic Frameworks for Nanodynamic Cancer Therapy
The development of covalent organic framework (COF) sonosensitizers with intrinsic
sonodynamic effects is highly desirable. However, such COFs are generally constructed …
sonodynamic effects is highly desirable. However, such COFs are generally constructed …
In situ hydrogel based on Cu–Fe3O4 nanoclusters exploits oxidative stress and the ferroptosis/cuproptosis pathway for chemodynamic therapy
Y Zhang, N Zhang, J Xing, Y Sun, X Jin, C Shen… - Biomaterials, 2024 - Elsevier
Chemodynamic therapy (CDT) involving the use of metal nanozymes presents new
opportunities for the treatment of deep-seated tumors. However, the lower ROS catalytic rate …
opportunities for the treatment of deep-seated tumors. However, the lower ROS catalytic rate …
A Defect‐Engineered Nanozyme for Targeted NIR‐II Photothermal Immunotherapy of Cancer
Multienzyme‐mimicking redox nanozymes, curated by defect engineering, in synergy with
immunotherapy offer promising prospects for safe and efficient cancer therapy. However, the …
immunotherapy offer promising prospects for safe and efficient cancer therapy. However, the …
Multichannel sonocatalysis amplifiers target IDH1‐mutated tumor plasticity and attenuate ros tolerance to repress malignant cholangiocarcinoma
D Wang, X Zhu, X Wang, Q Wang, K Yan… - Advanced Functional …, 2023 - Wiley Online Library
Tumor adaptation‐originated tumor tolerance that compensatory mechanisms (eg, isocitrate
dehydrogenase (IDH) mutation) jointly shape is the dominant obstacle of ROS therapy …
dehydrogenase (IDH) mutation) jointly shape is the dominant obstacle of ROS therapy …
A Sonication‐Activated Valence‐Variable Sono‐Sensitizer/Catalyst for Autography Inhibition/Ferroptosis‐Induced Tumor Nanotherapy
W Feng, Z Liu, L Xia, M Chen, X Dai… - Angewandte Chemie …, 2022 - Wiley Online Library
The effective deployment of reactive oxygen species (ROS)‐mediated oncotherapy in
practice remains challenging, mired by uncontrollable catalytic processes, stern reaction …
practice remains challenging, mired by uncontrollable catalytic processes, stern reaction …
Engineering dual catalytic nanomedicine for autophagy-augmented and ferroptosis-involved cancer nanotherapy
Chemodynamic therapy represents a distinct anti-tumor strategy by activating intratumoral
chemical catalytic reactions to produce highly toxic reactive oxygen species (ROS) from non …
chemical catalytic reactions to produce highly toxic reactive oxygen species (ROS) from non …